Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib.

Jacquin-Porretaz C, Nardin C, Blanc D, Aubin F, Gérard B, Drobacheff-Thiebaut C, Jacoulet P, Westeel V.

J Thorac Oncol. 2017 May;12(5):e47-e48. doi: 10.1016/j.jtho.2017.01.010. No abstract available.

PMID:
28434514
2.

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Cuzin L; Dat'AIDS Study group..

HIV Med. 2016 May;17(5):380-4. doi: 10.1111/hiv.12306. Epub 2015 Aug 26.

PMID:
27093565
3.

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach.

Cuzin L, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Flandre P; Dat'AIDS Study group..

Medicine (Baltimore). 2015 Sep;94(39):e1668. doi: 10.1097/MD.0000000000001668.

4.

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort..

BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1.

5.

Kaposi's sarcoma: a population-based cancer registry descriptive study of 57 consecutive cases diagnosed between 1977 and 2009.

Laresche C, Fournier E, Dupond AS, Woronoff AS, Drobacheff-Thiebaut C, Humbert P, Aubin F.

Int J Dermatol. 2014 Dec;53(12):e549-54. doi: 10.1111/ijd.12453. Epub 2014 Jun 25.

PMID:
24962354
6.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts..

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

7.

Can the "seek, test, treat, and retain" strategy be effective in France?

Cuzin L, Allavena C, Pugliese P, Rey D, Hoen B, Poizot-Martin I, Cabie A, Yazdanpanah Y; DATʼAIDS Study Group..

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):e119-21. doi: 10.1097/QAI.0b013e3182809f08. No abstract available.

PMID:
23933718
8.

Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).

Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D; ANRS 120 Fosivir Study Group..

AIDS Res Hum Retroviruses. 2012 Sep;28(9):972-80. Epub 2012 Mar 23.

PMID:
22353022
9.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, Calmy A, Balotta C, Damond F, Brun-Vezinet F, Chene G, Matheron S; ACHIEV2E Collaboration Study Group..

Clin Infect Dis. 2011 May;52(10):1257-66. doi: 10.1093/cid/cir123.

PMID:
21507923
10.

Detection of human papillomavirus DNA in plucked eyebrow hair from HIV-infected patients.

Biver-Dalle C, Gheit T, Drobacheff-Thiebaut C, Vidal C, Tommasino M, Humbert P, Pretet JL, Mougin C, Aubin F.

J Invest Dermatol. 2010 Oct;130(10):2499-502. doi: 10.1038/jid.2010.147. Epub 2010 Jun 3. No abstract available.

11.

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.

Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, Bonnefont-Rousselot D, Pétour P, Aubron-Olivier C, Costagliola D, Katlama C; TOTEM trial group..

J Antimicrob Chemother. 2010 Mar;65(3):556-61. doi: 10.1093/jac/dkp462. Epub 2010 Jan 6.

PMID:
20053692
12.

[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].

Pitche P, Drobacheff-Thiebaut C, Gavignet B, Mercier M, Laurent R.

Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):970-4. French.

PMID:
16446639
13.

[Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients].

Pelletier F, Drobacheff-Thiebaut C, Aubin F, Venier AG, Mougin C, Laurent R.

Ann Dermatol Venereol. 2004 Nov;131(11):947-51. French.

PMID:
15602380

Supplemental Content

Loading ...
Support Center